Drug intelligence / Profile preview

AU-012

Development stage: Preclinical
Lead developer: Aura Biosciences
Administration: Intravesical

Overview

**AU-012** is an investigational oncology product candidate from **Aura Biosciences**. Public-source mentions indicate it was being developed for **bladder cancer** and **head and neck cancer**, but detailed information on its exact molecular composition, modality, route, and mechanism has not been clearly disclosed in the public sources identified. Available evidence suggests it is a distinct Aura program separate from AU-011, but the public record located here is too sparse to confidently assign a precise mechanism of action or development stage beyond early development mention.

Beyond the preview

Go deeper on AU-012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AU-012.

Explore the full profile